Office of the Prime Minister / Cabinet du Premier ministre

[Guest guest]

I thought my friends would like to see the following.

It is great to get a response from our Prime Minister, Harper.

Sometimes it pays to know people in high places.

Office of the Prime Minister / Cabinet du Premier ministre

Dear Mr. Beckingham:

On behalf of the Right Honourable Harper, I would like to

acknowledge receipt of your e-mail correspondence regarding

Charcot-Marie-Tooth Disease.

Please be assured that your comments have been carefully reviewed. I have

taken the liberty of forwrading your e-mail to the Honourable Leona

Aglukkaq, Minister of Health, in order that she may be made aware of your

interest in this matter.

Thank you for writing to the Prime Minister.

A. Opalick

Executive Correspondence Officer

for the Prime Minister's Office

Agent de correspondance

de la haute direction

pour le Cabinet du Premier ministre

>>> From : Dave Beckingham dgbeckingham@... Received : 03 Dec

>>> 2010 04:13:17 PM >>>

>>> Subject : CMT 1A: Pharnext Pleodrug PXT3003 Phase 2 Trials

>>> BEGIN >>>>

Good Day:

As a Conservative Member and supporter (very little financial/CPP

Disability), I am sending you the following important and encouraging

article.

I do indeed have CMT1A, a neuromuscular disease. CMT1A is the most common

form of hereditary neuropathy and it affects 1 in 2,500 people. This equates

to 13,600 Canadians. CMT (Charcot-Marie-Tooth) is named after the 3 doctors

who discovered the disease in 1885. There were 2 French doctors, Jean

Charcot & Pierre Marie along with an English doctor named Tooth. Jean

Charcot also discovered ALS (Lou Gehrig's disease). It is interesting that

these trials are being done in France.

It would be a blessing if Health Canada could get involved in these clinical

trials, or at least keep abreast of these trials. I am presently 61 years

old, so this may not happen in my time, but perhaps my son's time who is

only 21 years old. Your assistance would be greatly appreciated.

Kindest regards,

G. Beckingham......Port Elgin, ON.

519-832-3225

dgbeckingham@...,

From: -owner

Sent: Friday, December 03, 2010 12:14 PM

] CMT 1A: Pharnext Pleodrug PXT3003 Phase 2 Trials BEGIN

PHARNEXT Receives Clinical Trial Authorization for a Phase II Study with the

First Drug Generated by Its PleotherapyTM Technology

http://www.benzinga.com/press-releases/10/12/b665794/pharnext-receives-clinical-\

trial-authorization-for-a-phase-ii-study

Pharnext SAS, a biopharmaceutical company specializing in the development of

innovative treatments for severe neurological diseases and other major unmet

medical needs, today announced that the French Agency for Healthcare Product

Safety (AFSSAPS) has authorized a Phase II clinical trial with the first

drug (a Pleodrug?) generated by the company's Pleotherapy? technology

platform in patients suffering from Charcot-Marie Tooth disease type 1A

(CMT1A) - a chronic, severe, invalidating and currently incurable

neuromuscular disease which affects 3 million people worldwide.

Pharnext's first Pleodrug? is a composed of three generic drugs in a new

formulation (a syrup) and which have already received marketing approval for

therapeutic indications other than CMT1A. Given that the three compounds are

present in the Pleodrug? at 10- to 100-fold lower doses than in their usual

indication, the clinical development programme in humans has not

necessitated the performance of a Phase I safety trial and has enabled

Pharnext to obtain a Phase II clinical trial authorization directly after

just 3 years (rather than the 8 years required on average for most drugs).

The forthcoming Phase II randomized, comparative, placebo-controlled

clinical trial will evaluate the safety, efficacy, pharmacodynamics and

pharmacokinetics of PXT3003 in patients suffering from CMT1A. The trial will

be performed in 5 investigating centres (Timone University Hospital in

Marseilles, Salpêtrière Hospital in Paris, Limoges University Hospital,

Lyons Sud University Hospital and Pierre Swynghedauw Hospital in Lille) and

will be initiated first at Timone University Hospital (coordinating

investigator: Shahram Attarian MD) in December.

'This first clinical trial authorization constitutes key proof of the

efficiency of our Pleotherapy? technology. We are continuing to screen for

Pleodrugs? for six other serious diseases (including Alzheimer's disease);

our model means that we can hope to make Pleodrugs? available to patient

more rapidly', emphasized Pharnext founder and CEO Professor Cohen.

'We are delighted to be able to start the first clinical trial of our first

Pleodrug? for the treatment of Charcot-Marie-Tooth disease', he concluded.

Pharnext has designed a novel, proprietary platform (Pleotherapy?) based on

network pharmacology. The company's discovery engine identifies rational

drug combinations (Pleodrugs?) made up of individual Pleocompounds?. This

innovative approach could provide a solution to the ongoing and worrying

decline in pharmaceutical pipeline productivity.

About Pharnext

Pharnext is a biopharmaceutical company focused on discovering, developing

and licensing new pharmaceutical treatments based on intelligent

Pleocompounds? that form the basis of Pleodrugs?. Pharnext was founded in

Paris, France in April, 2007, by Professor Cohen, MD, PhD, his

research group (composed of pioneers in genome science and technology) and

Philippe Pouletty, MD (General Partner at Truffle Capital). Thanks to

Truffle Capital's founding investment, strong support from OSEO, a grant

from the French Muscular Dystrophy Association (AFM) and the benefits of

France's research tax credit scheme, Pharnext has developed a novel,

proprietary platform (PleotherapyTM) based on network pharmacology and which

may provide a solution for the current decline in pharmaceutical pipeline

productivity. Pharnext is advised by La Compagnie Financière Edmond de

Rothschild.